Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry Trachtenberg

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
American Heart Journal|March 12, 2011
Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacyBarry Trachtenberg, Darcy L Velazquez, Adam R Williams, et al.
Heart (British Cardiac Society)|January 24, 2024
Moving towards establishing centres of excellence in cardiac amyloidosis: an International Cardio-Oncology Society statementRichard Cheng, Michelle M Kittleson, Ashutosh D Wechalekar, et al.
Circulation Research|January 23, 2014
Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trialViky Y Suncion, Eduard Ghersin, Joel E Fishman, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
American Heart Journal|March 12, 2011
Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacyBarry Trachtenberg, Darcy L Velazquez, Adam R Williams, et al.
Heart (British Cardiac Society)|January 24, 2024
Moving towards establishing centres of excellence in cardiac amyloidosis: an International Cardio-Oncology Society statementRichard Cheng, Michelle M Kittleson, Ashutosh D Wechalekar, et al.
Circulation Research|January 23, 2014
Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trialViky Y Suncion, Eduard Ghersin, Joel E Fishman, et al.
Pageof 5